AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01502371
Drug: Placebo Dry Powder Inhaler (DPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DPI, 1 puff QD for 12 weeks
Trial: NCT03298347
Drug: 20mg/kg of caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg of caffeine is given to treat AOP
Trial: NCT03035890
Drug: Immuno-Therapeutic Agent
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity.
Trial: NCT01640080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
Trial: NCT04592536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
Trial: NCT02774343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
Trial: NCT00549419
Drug: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Control group will be assessed using the standard care of traditional vital signs
Trial: NCT00549419
Drug: Goal-directed hemodynamic therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Trial: NCT00549419
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Trial: NCT03433378
Drug: RETIN-A® (tretinoin) cream, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RETIN-A® (tretinoin) cream, 0.05%
Trial: NCT03433378
Drug: Vehicle of the test product
RxNorm normalized name: The Magic Bullet Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of the test product
Trial: NCT03074045
Drug: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
Trial: NCT02985255
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant Arm
Trial: NCT01554371
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02515526
Drug: caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference period
Trial: NCT02515526
Drug: ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test period
Trial: NCT00002855
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002855
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02196493
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250mg azithromycin three times per week for 12 weeks
Trial: NCT02936154
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00642928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day during 4 weeks
Trial: NCT00642928
Drug: BF 2.649 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one BF 2.649 capsule of 5 mg per day during 4 weeks
Trial: NCT00642928
Drug: BF 2.649 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One BF 2.649 capsule of 10 mg per day during 4 weeks
Trial: NCT00642928
Drug: BF 2.649 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One BF 2.649 capsule of 20 mg per day during 4 weeks
Trial: NCT00642928
Drug: BF 2.649 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One BF 2.649 capsule of 40 mg per day during 4 weeks
Trial: NCT02682498
Drug: (Bupivacaine Liposome Injectable Suspension)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
Trial: NCT04192812
Drug: PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
Trial: NCT04192812
Drug: NO GnRHa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
Trial: NCT04368533
Drug: A standard children's toothpaste containing 1500 ppm fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
Trial: NCT03049306
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
Trial: NCT00884884
Drug: Double Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily
Trial: NCT02600988
Drug: 1000IU/day of Vitamine D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a specified dose of Vitamine D
Trial: NCT02600988
Drug: 5000IU/day of Vitamine D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a specified dose of Vitamine D
Trial: NCT04160000
Drug: Empiric heart failure drug therapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
Trial: NCT01507753
Drug: Omega-3 Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
Trial: NCT00642499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04758156
Drug: CleanViewAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1L PEG + ascorbic acid bowel preparation for colonoscopy
Trial: NCT04758156
Drug: SUPREP
RxNorm normalized name: Suprep Bowel Prep Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sulfate solution for colonoscopy bowel preparation
Trial: NCT00509925
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Trial: NCT00242463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03761407
Drug: 100 mg GRT0151Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsule (1 x 100 mg capsule)
Trial: NCT03761407
Drug: 125 mg GRT0151Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
Trial: NCT00497198
Drug: Placebo of MCI-196 Tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
Trial: NCT04915456
Drug: Systemic Steroid (Prednisolone)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
Trial: NCT02813447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00312364
Drug: MRE0094
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092365
Drug: MK0966, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003212
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03683914
Drug: Dinoprostone 3Mg Vaginal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
Trial: NCT03683914
Drug: placebo vaginal tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
Trial: NCT00664456
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
Trial: NCT00664456
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
Trial: NCT02453087
Drug: DCDS0780A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive escalating doses of DCDS0780A as intravenous infusion.
Trial: NCT01702389
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002793
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002793
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00936520
Drug: SAR 1118 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Trial: NCT00936520
Drug: SAR 1118 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Trial: NCT00936520
Drug: SAR 1118 5.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Trial: NCT00872469
Drug: Placebo [Saline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched to active comparator
Trial: NCT03249402
Drug: Ethinyl Estradiol + Levonorgestrel
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
Trial: NCT02208882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00634322
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV or po given every 6 hours
Trial: NCT00113893
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Trial: NCT00113893
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Trial: NCT03385057
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
Trial: NCT03385057
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
Trial: NCT00654329
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl, nasal transmucosal, 2 micrograms/kilogram
Trial: NCT02206087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversal of heparin-induced anticoagulation
Trial: NCT02206087
Drug: Heparin Sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00508859
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02459236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03749148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00004097
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00349245
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01631617
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
Trial: NCT02489318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo orally once daily in each 28 day treatment cycles.
Trial: NCT02489318
Drug: Androgen Deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Trial: NCT00726388
Drug: DIC075V (intravenous diclofenac sodium)
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: multiple doses up to 5 days
Trial: NCT04312971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
Trial: NCT04312971
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
Trial: NCT02435381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment only
Trial: NCT04500808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo from Day 1 up to Day 13.
Trial: NCT02110225
Drug: rhNGF 60 µg/ml eye drops solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Trial: NCT02110225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Trial: NCT02176018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01116440
Drug: BGS649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
Trial: NCT01116440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
Trial: NCT00666835
Drug: ERYPO®, Janssen-Cilag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for i.v. injection
Trial: NCT01842399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x/day orally
Trial: NCT04127019
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide chemotherapy (injection)
Trial: NCT03086070
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
Trial: NCT01552668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive Placebo twice daily
Trial: NCT03689153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo intravenously.
Trial: NCT02862431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Trial: NCT00003402
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00220116
Drug: Capecitabine, Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02519452
Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Trial: NCT04175808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT00291642
Drug: Placebo drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use
Trial: NCT03134976
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
Trial: NCT03759028
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.